Objective:

The article examines the objective, findings, and clinical context described in FDA flags vision loss risk with GLP-1 drugs.

Approach:

• Safety action: The FDA directed manufacturers to add NAION risk information to the Warnings and Precautions section of prescribing information for all marketed GLP-1 receptor agonists.
• Evidence reviewed: The FDA reviewed clinical trials, observational studies, postmarketing reports, and animal data, and conducted a Sentinel database cohort study of adults with type 2 diabetes who initiated GLP-1, SGLT2, or DPP4 inhibitors between 2019 and 2024.

Key Findings:

• In a meta-analysis of 126 randomized trials involving 134,253 patients, 15 probable NAION cases were identified: 10 among 78,217 GLP-1 RA recipients and 5 among 56,036 comparator recipients; all comparator cases occurred in placebo groups.
• Estimated NAION incidence in the meta-analysis was 6.4 per 100,000 person-years with GLP-1 RAs and 3.8 with comparators.
• In the Sentinel study, incidence ranged from 30 to 32 cases per 100,000 person-years with GLP-1 RAs, compared with 31 for SGLT2 inhibitors and 26 for DPP4 inhibitors. Risk was significantly higher versus DPP4 inhibitors, but not versus SGLT2 inhibitors.
• The FDA reported NAION cases with all currently marketed GLP-1 RAs. Its animal-data review did not identify a mechanism explaining the potential increased risk.

Interpretation:

The FDA described a potential increased risk of NAION, a rare condition that can cause sudden, painless, potentially permanent vision loss. It noted that postmarketing reports are difficult to interpret because NAION risk factors overlap with conditions common among GLP-1 RA users.

Limitations:

• The FDA said overlapping risk factors, including diabetes, hypertension, and sleep apnea, complicate interpretation of postmarketing reports.
• The animal-data review did not identify a mechanism explaining the potential risk.

Conclusion:

The FDA advises health care professionals to tell patients to report sudden, painless visual changes immediately and to promptly refer suspected NAION cases for ophthalmologic evaluation. It recommends considering GLP-1 RA discontinuation after NAION unless treatment benefits clearly outweigh risks.

Sources:

• FDA